Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Article too big to display. Click here to view on the SEC website

Genmab AS (NASDAQ:GMAB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Genmab AS Charts.

Genmab AS (NASDAQ:GMAB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Genmab AS Charts.

News Genmab AS

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Montag 9 Dezember 2024 (4 Wochen vor) • Business Wire

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Sonntag 8 Dezember 2024 (4 Wochen vor) • Business Wire

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Sonntag 8 Dezember 2024 (4 Wochen vor) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 4 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 3 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 3 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 27 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 21 November 2024 (1 Monat vor) • Edgar (US Regulatory)

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
Dienstag 5 November 2024 (2 Monate vor) • Business Wire

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Sonntag 15 September 2024 (4 Monate vor) • Business Wire

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 11 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 10 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Weitere Genmab AS News-Artikel

DJ Industrial Average In...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen